NCT00077844View on ClinicalTrials.gov

Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

3,532

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

September 30, 2005

Study Completion Date

September 30, 2005

Conditions
Percutaneous Coronary Intervention
Interventions
DRUG

Enoxaparin sodium

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY